QCG
CRSP icon

Quadrant Capital Group’s CRISPR Therapeutics CRSP Stock Holding History

Quadrant Capital Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.52K Hold
158
– – ﹤0.01% 2266
2025
Q4 		$8.29K Sell
158
-36
-19% -$2.16K ﹤0.01% 2251
2025
Q3 		$12.6K Buy
+194
New +$11.1K ﹤0.01% 2100
2025
Q2 		– Sell
-67
Closed -$2.28K – 1631
2025
Q1 		$2.28K Sell
67
-28
-29% -$1.19K ﹤0.01% 2492
2024
Q4 		$3.74K Buy
95
+42
+79% +$1.98K ﹤0.01% 2375
2024
Q3 		$2.49K Sell
53
-46
-46% -$2.33K ﹤0.01% 2457
2024
Q2 		$5.35K Hold
99
– – ﹤0.01% 2278
2024
Q1 		$6.75K Sell
99
-36
-27% -$2.58K ﹤0.01% 2238
2023
Q4 		$8.45K Sell
135
-141
-51% -$7.79K ﹤0.01% 2128
2023
Q3 		$12.5K Buy
276
+248
+886% +$12.8K ﹤0.01% 1902
2023
Q2 		$1.57K Hold
28
– – ﹤0.01% 2458
2023
Q1 		$1.27K Sell
28
-124
-82% -$6.02K ﹤0.01% 2512
2022
Q4 		$6.18K Buy
152
+105
+223% +$5.57K ﹤0.01% 2147
2022
Q3 		$3K Sell
47
-4
-8% -$290 ﹤0.01% 2262
2022
Q2 		$3K Sell
51
-111
-69% -$6.53K ﹤0.01% 2096
2022
Q1 		$10K Buy
+162
New +$10.2K ﹤0.01% 1635
2021
Q2 		– Sell
-5
Closed -$1K – 2433
2021
Q1 		$1K Buy
+5
New +$755 ﹤0.01% 2191

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quadrant Capital Group's CRSP Position: Q1 2026 in Review

Quadrant Capital Group held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 158 shares worth $7.52K. The position accounts for ﹤0.01% of the portfolio, ranked #2266.

Quadrant Capital Group first reported a position in CRSP in Q1 2021 and has held it in 17 quarters since. The position peaked at $12.6K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Quadrant Capital Group held 158 shares of CRISPR Therapeutics worth $7.52K as of Q1 2026.
  • Quadrant Capital Group left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2266 holding.
  • Quadrant Capital Group first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • Quadrant Capital Group's CRISPR Therapeutics position peaked at $12.6K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.